Entrada Therapeutics Inc. (TRDA)
NASDAQ (NMS) NASDAQ (NMS) Primary 
Entrada Therapeutics, Inc. (TRDA) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Entrada Therapeutics, Inc. (TRDA) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Entrada Therapeutics, Inc. (TRDA) Q1 2026 Earnings Call Transcript
Entrada Therapeutics, Inc. (TRDA) Q1 2026 Earnings Call Transcript
Entrada Therapeutics, Inc. (TRDA) Reports Q1 Loss, Misses Revenue Estimates
Entrada Therapeutics, Inc. (TRDA) came out with a quarterly loss of $0.95 per share versus the Zacks Consensus Estimate of a loss of $1.06. This compares to a loss of $0.42 per share a year ago.
Entrada Therapeutics (TRDA) Surges 8.9%: Is This an Indication of Further Gains?
Entrada Therapeutics (TRDA) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Earnings Preview: Entrada Therapeutics, Inc. (TRDA) Q4 Earnings Expected to Decline
Entrada Therapeutics (TRDA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Entrada Therapeutics, Inc. (TRDA) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Entrada Therapeutics, Inc. (TRDA) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Entrada Therapeutics, Inc. (TRDA) Reports Q3 Loss, Misses Revenue Estimates
Entrada Therapeutics, Inc. (TRDA) came out with a quarterly loss of $1.06 per share versus the Zacks Consensus Estimate of a loss of $1.04. This compares to a loss of $0.35 per share a year ago.
Entrada Therapeutics, Inc. - Special Call
Entrada Therapeutics, Inc. - Special Call Company Participants Dipal Doshi - CEO & Director Conference Call Participants Raghuram Selvaraju - H.C. Wainwright & Co, LLC, Research Division Presentation Raghuram Selvaraju H.C.
Entrada Therapeutics, Inc. (TRDA) Reports Q2 Loss, Lags Revenue Estimates
Entrada Therapeutics, Inc. (TRDA) came out with a quarterly loss of $1.04 per share versus the Zacks Consensus Estimate of a loss of $0.86. This compares to earnings of $1.55 per share a year ago.
Entrada Therapeutics (TRDA) Soars 5.6%: Is Further Upside Left in the Stock?
Entrada Therapeutics (TRDA) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Entrada Therapeutics, Inc. (TRDA) Reports Q1 Loss, Tops Revenue Estimates
Entrada Therapeutics, Inc. (TRDA) came out with a quarterly loss of $0.42 per share versus the Zacks Consensus Estimate of a loss of $0.78. This compares to earnings of $0.68 per share a year ago.
Analysts Estimate Entrada Therapeutics, Inc. (TRDA) to Report a Decline in Earnings: What to Look Out for
Entrada Therapeutics (TRDA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
